What is Augmedics?
Augmedics operates at the intersection of medical technology and augmented reality, providing surgeons with real-time, heads-up display guidance during complex procedures. By projecting 3D anatomical structures directly onto the surgeon's field of view, the company addresses critical unmet clinical needs, reducing the cognitive load and technical uncertainty inherent in traditional surgical navigation. This proprietary platform is positioned to redefine the standard of care, moving beyond static imaging to dynamic, interactive surgical assistance that enhances precision and patient outcomes across various medical specialties.
How much funding has Augmedics raised?
Augmedics has raised a total of $141.8M across 4 funding rounds:
Series A
$8.3M
Series B
$15M
Unspecified
$36M
Series D
$82.5M
Series A (2017): $8.3M with participation from AO Invest and Terra Venture Partners
Series B (2020): $15M, investors not publicly disclosed
Unspecified (2021): $36M supported by Almeda Ventures, XR Investment, H.I.G. Capital, Hospital Corporation of America, and Revival Healthcare Capital
Series D (2023): $82.5M featuring Revival Healthcare Capital, H.I.G. Capital, Almeda Ventures, and Cpmg
Key Investors in Augmedics
H.I.G. Capital
A global alternative investment firm managing over $70 billion in assets, specializing in private equity and growth equity for companies ranging from mid-sized firms to large enterprises.
Almeda Ventures
The first HealthTech-focused public R&D partnership that invests globally in medical devices, digital health, and bio-convergence to drive innovation in patient care.
Terra Venture Partners
An Israeli multi-stage venture capital firm that partners with entrepreneurs to develop impact-driven technologies in healthcare, sustainability, and digitalization.
What's next for Augmedics?
With the recent infusion of $82.5M, Augmedics is well-positioned to scale its commercial operations and deepen its R&D pipeline. The company's trajectory, marked by consistent backing from major venture capital and private equity firms, suggests a transition toward broader enterprise-level adoption. Future strategic initiatives will likely focus on expanding the clinical applications of its AR platform, securing additional regulatory clearances, and strengthening its global distribution network to solidify its leadership in the digital health and surgical robotics ecosystem.
See full Augmedics company page
